The Filing Desk

Fulcrum Therapeutics

FULC · Nasdaq · Health Care · Financials, fiscal 2018 to 2025

FULC · Last close · November 19, 2026
$3.71
Value Fulcrum Therapeutics yourself

Fulcrum Therapeutics' revenue fell 100.0% to $0 million in fiscal 2025. Free cash flow was −$60 million. The diluted share count rose 2.2%.

FULCRUM THERAPEUTICS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 24, 2026 · 0001193125-26-065197 Updated
Revenue
$0M
100.0%
Net margin
—
 
Net income
−$75M
 
Free cash flow
−$60M
 
Return on equity
−25.3%
21.2 pts
Market cap
$283M
Nov 19 close
P/E
—
Loss: no P/E

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. The SEC's structured data gives diluted share counts for fiscal 2018 to 2025 in thousands without saying so; they are shown here in millions, which makes net income per share match the reported earnings per share. Operating margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs. Net margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs. Free cash flow margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Fulcrum Therapeutics does

Fulcrum Therapeutics is a clinical-stage drug company, so it has no approved products. It develops small-molecule medicines for rare diseases with a known genetic cause.

Its lead product candidate is pociredir, a pill designed to raise fetal hemoglobin, a form of the oxygen-carrying protein that is normally made before birth, as a treatment for sickle cell disease. It has finished dosing in a Phase 1b trial called PIONEER in adults with the disease and says it saw increases in fetal hemoglobin and improvements in markers of anemia and red blood cell breakdown. It is starting an open-label extension trial to study longer-term safety.

The company also uses a discovery approach to find drug targets that control gene activity. It presented preclinical data on FTX-6274, a prostate cancer candidate, in 2025. It decided not to advance its program for bone marrow failure syndromes and will focus on pociredir and its blood disorder programs.

Its biggest risks, as it describes them

  • Losses since its start, and a need for substantial additional funding.
  • It has only one product candidate in clinical trials, so its success depends on pociredir.
  • Serious side effects found in its drugs, or in others' drugs of the same class, could stop development.
  • It relies on contract manufacturers to make its drug candidates.
From Fulcrum Therapeutics's annual report on Form 10-K, filed February 24, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Fulcrum Therapeutics lost money in fiscal 2025: a net loss of $75 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments35352658198
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio11.8x12.4x17.7x22.6x27.4x
Quick ratio11.8x12.4x17.7x22.6x27.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Fulcrum Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $1.5 million of Fulcrum Therapeutics shares on the open market, and 4 insiders sold $58.8 million, $449,150 of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jul 17, 2026Kevin Tang10% ownerBought50,945$3.52$179,326Form 4
Jul 16, 2026Kevin Tang10% ownerBought116,671$3.56$415,349Form 4
Jul 15, 2026Tang Capital Management Llc10% ownerBought107,377$3.56$382,262Form 4
Jul 14, 2026Tang Capital Management Llc10% ownerBought129,603$3.57$462,906Form 4
Jul 13, 2026Tang Capital Management Llc10% ownerBought12,966$3.54$45,900Form 4
Jun 26, 2026Alan EzekowitzDirectorSold plan18,000$3.65$65,700Form 4
Feb 2, 2026Robert J GouldDirectorSold plan15,000$10.72$160,800Form 4
Jan 2, 2026Robert J GouldDirectorSold plan15,000$11.87$178,050Form 4
Dec 15, 2025Curtis Gale OltmansChief Legal OfficerSold plan3,452$12.92$44,600Form 4
Dec 8, 2025RA Capital Healthcare Fund LP10% ownerSold4,175,139$13.98$58.4 millionForm 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−3,316.8%2,748.9%—
Altman Z''7.4613.3820.53
Accruals ratio−2.6%−2.9%−4.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rosePassPassPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailPassFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Fulcrum Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Fulcrum TherapeuticsFY25−100.0%—————
Aardvark TherapeuticsFY25——————Compare
ABVC BioPharmaFY25−41.9%−2,416.0%————Compare
Acadia PharmaceuticalsFY2511.9%9.8%9.8%———Compare
Aclaris TherapeuticsFY25−58.2%−975.9%−603.4%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

8 years of figures

Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue——91963800
Revenue growth———117.2%−66.9%−55.8%2,752.1%−100.0%
Gross profit————————
Research and development2571597077726356
Operating income−34−84−72−81−113−111−22−85
Net income−33−83−71−81−110−97−10−75
Diluted EPS (US$)−31.14−8.13−2.79−2.29−2.44−1.59−0.16−1.18
Diluted shares (millions)111253545616263
Cash flow
Cash from operations−23−40−54−78−97−91−2−60
Capital expenditure91122000
Free cash flow−32−40−55−80−99−91−2−60
Dividends paid00000000
Share buybacks00000000
Acquisitions00000000
Stock-based compensation2471113151512
Balance sheet at fiscal year end
Cash and short-term investments73975735352658198
Debt incl. finance leases————————
Total assets86110130235227258261366
Total liabilities1023342428221817
Shareholders' equity−648795212199235243349
Margins and ratios
Gross margin————————
Operating margin——−811.6%−423.0%−1,774.8%−3,945.2%−27.4%—
Net margin——−802.7%−421.9%−1,732.4%−3,470.1%−12.2%—
Free cash flow margin——−623.3%−418.5%−1,561.2%−3,261.1%−3.1%—
Rule of 40 (growth + FCF margin)———−301.3%−1,628.1%−3,316.8%2,748.9%—
Return on capital————————
Return on equity—−704.1%−77.7%−52.7%−53.5%−44.8%−4.1%−25.3%
Return on assets—−84.3%−59.0%−44.4%−47.6%−40.2%−3.8%−23.9%
Net debt to EBITDA————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Fulcrum Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Fulcrum Therapeutics.